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5T4 as a target for immunotherapy in 
renal cell carcinoma
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“5T4 restricted expression on tumor tissues and its 
association with tumor progression and poor prognosis  
has driven the development of 5T4 vaccine and 
antibody- targeted immunotherapies.”
Renal cell carcinoma (RCC) accounts for 
2% of all new cancer cases worldwide [1]. The 
management of metastatic RCC (MRCC) 
represents a therapeutic challenge. Radical 
nephrectomy can be curative for early-stage 
disease; however, approximately a third of 
patients present with metastatic disease, 
and a further third will subsequently relapse 
after initial surgery [2,3]. MRCC is resist-
ant to cytotoxic chemo- [4], hormone- and 
radio-therapies [5] and responds modestly 
to immunotherapies, including cyto-
kines, monoclonal antibodies and tumor 
vaccines [6]. Recently developed targeted 
agents, such as the VEGF receptor and 
mTOR inhibitors, are currently the stan-
dard of care for most MRCC patients. 
Although they provide good rates of dis-
ease control and have relatively manage-
able toxicities for most patients, the ben-
efit is relatively limited and there are few 
if any durable remissions once treatment 
is stopped [7]. In view of the occasional 
spontaneous regression of metastasis after 
nephrectomy [8] and the durable objec-
tive response observed following admini-
stration of immunomodulatory therapies, 
such as IL-2 [9], RCC is considered an 
immune-sensitive tumor and attempts to 
increase the rate of sustained responses 
using immunotherapeutic modalities 
are justified.
5T4 oncofetal antigen
A useful target tumor-associated antigen 
(TAA) for RCC would be expressed by 
most RCCs but have no or only lim-
ited expression in normal tissues [10,11]. 
5T4 oncofetal antigen, a 72-kDa mem-
brane glycoprotein, was discovered while 
searching for molecules with invasive 
properties likely to be shared by tropho-
blast and cancer cells [12]. It is expressed 
by many different carcinomas while 
showing only low levels in some normal 
tissues [13]. Our immuno histo chemistry 
studies have shown that the major-
ity of RCCs strongly express 5T4 [14], 
making this tumor an attractive target 
for 5T4-directed immunotherapy. 5T4 
expression has been shown to influence 
adhesion, cytoskeletal organization and 
motility properties [15–17], which might 
account for its association with a poorer 
clinical outcome in some cancers. Recent 
studies have shown that upregulation 
of 5T4 expression is a marker of loss of 
pluripotency in the early differentiation 
of human and murine embryonic stem 
cells [18,19] and forms an integrated com-
ponent of an epithelial mesenchymal 
transition [20,21]. Epithelial mesenchy-
mal transition occurs during embryonic 
development and is believed to be impor-
tant for the metastatic spread of epithelial 
tumors [22]. 5T4 restricted expression on 
tumor tissues and its association with 
tumor progression and poor prognosis has 
driven the development of the 5T4 vaccine 
and antibody-targeted immunotherapies.
5T4 vaccine (TroVax®)
TroVax® consists of a highly attenu-
ated and efficacious modified vaccinia 
virus Ankara (MVA) strain, expressing 
human 5T4 (h5T4). Preclinical studies 
in mice have demonstrated, in active 
treatment studies, that inoculation with 
MVA-h5T4 was able to treat established 
CT26-h5T4 lung tumors and B16-h5T4 
subcutaneous tumors. Furthermore, vac-
cination with MVA-mouse 5T4 (m5T4) 
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was immunogenic (breaking tolerance) in mice but had no signs 
of autoimmune toxicity [23]. In humans, CD8+ and CD4+ T 
cells recognizing h5T4 can be generated from peripheral blood 
lymphocytes of healthy individuals [24,25]. Importantly, h5T4-
specific CD4+ T cells are more readily generated with prior 
depletion of CD25+ Tregs. These observations imply that 
the availability of the h5T4 repertoire may only be optimally 
accessed in the absence of Treg activity, and these cells play an 
important role in controlling their activation/expansion.
Overall these data have supported the use of TroVax in several 
Phase I and II studies in cancer patients that have provided evi-
dence of immunogenicity and safety [26–28]. In a recent Phase II 
trial, two TroVax vaccinations were given to patients both pre- 
and post-surgical resection of liver metastases secondary to 
colorectal cancer. 5T4-specific cellular responses were assessed 
at entry and 2 weeks after each vaccination by proliferation 
of fresh lymphocytes and ELISA for antibody responses, and 
95% of patients showed a 5T4-specific cellular and/or humoral 
response [29]. In patients who received at least four vaccina-
tions and potentially curative surgery, those with above median 
5T4-specific proliferative responses or T-cell infiltration into 
the resected tumor showed significantly longer survival com-
pared with those with below median responses [29]. These data 
suggest that the magnitude of 5T4 proliferative responses and 
the density of CD3 cells in colorectal cancer liver metastases 
are associated with longer survival. We also assessed the levels 
of systemic Tregs, plasma cytokine levels, phenotype of tumor-
infiltrating lymphocytes (TILs), including Tregs, and tumor 
HLA class I loss of expression. More than half of the patients 
showed phenotypes consistent with relative immunosuppression 
and/or escape, making it difficult to define any simple correla-
tion with clinical outcome [30]. Tregs are important regulators 
for immune homeostasis but they are also able to suppress anti-
tumor immunity and consequently impair immunotherapy. 
Another study has shown that Tregs inhibiting h5T4-specific 
immune responses are increased in colorectal cancer patients, 
compared with healthy donors [31].
“…data have supported the use of TroVax in several 
Phase I and II studies in cancer patients that have 
provided evidence of immunogenicity and safety.”
Phase II trials of TroVax combined with IL-2 or IFN-a in 
MRCC have also established immunogenicity and safety [32–35]. 
Administration of TroVax with IFN-a was shown to be safe 
with evidence of 5T4-specific immune response and encourag-
ing survival [32,34]. A randomized, placebo-controlled Phase III 
study (TroVax Renal Immunotherapy Survival Trial [TRIST]), 
comparing TroVax or placebo in combination with standard 
treatment has recently been completed. This study investigated 
whether TroVax added to first-line standard of care (IFN-a, 
IL-2 or sunitinib were allowed as standard care according to 
local preference) prolonged the survival of patients with locally 
advanced or metastatic clear cell renal adenocarcinoma. TroVax 
was well tolerated when administered alongside IL-2, IFN-a 
or sunitinib. While the primary end point was not met, a sig-
nificant survival advantage was seen in good-prognosis patients 
treated with IL-2 plus TroVax compared with patients treated 
with IL-2 alone [36]. This combination of IL-2 and TroVax 
appears promising and may be worthy of exploring further in 
this subgroup of patients. Antibody responses against 5T4 were 
induced in most TroVax-treated patients and were associated 
with enhanced survival irrespective of the health status of the 
patient [36].
“The group of patients receiving the highest drug 
[5T4Fab–SEA] exposure lived almost twice as long 
as expected, while the low-dose group lived as 
expected from their Motzer scores.”
The lack of benefit seen in other subgroups may reflect difficul-
ties in optimizing immune responses, and obtaining the optimal 
type of immune response especially when combinations of thera-
pies are used. For example, it has been shown that a significant 
increased frequency of systemic Treg levels in RCC patients com-
pared with normal donors is observed and this was associated 
with adverse overall survival [37]. Although CD4+ T cells spon-
taneously recognizing a 5T4 epitope restricted by HLA-DR have 
been identified in TILs from a RCC lung metastasis [24], such 
h5T4-specific CD4+ T cells that may be boosted or induced by 
vaccination could deliver both positive and negative modulation 
of anti-tumor responses. Importantly, in the latter work, these 
cells secreted both IFN-g and IL-10, which could indicate a Treg 
phenotype. Approaches to modulating Treg activity and boosting 
5T4 immunity in patients are in progress. A Phase I trial to assess 
the feasibility and safety of adoptive transfer of Treg-depleted 
autologous T cells following conditioning chemotherapy in six 
patients with advanced RCC reported one patient with increased 
specific response to 5T4 coinciding with the nadir of Treg [38]. 
However, for routine clinical practice, simplified methods of 
Treg depletion are required.
5T4 antibody-directed superantigen therapy
The exploitation of active immunization may be particularly 
favorable for TAA where tolerance is incomplete but passive 
immunization may offer an additional strategy where the 
immune repertoire is affected by either tolerance, immunosup-
pression or tumor escape. Tumor-targeted superantigens treat 
tumors via the local activation of the patients’ cytotoxic T cells 
through a process termed superantigen antibody-dependent 
cellular cytotoxicity. Using this approach, 5T4 was targeted by 
genetically fusing a murine Fab fragment of the monoclonal 
antibody 5T4 to a mutated superantigen staphylococcal entero-
toxin A (SEA) and the maximum tolerated dose and safety 
was established in a trial in non-small-cell lung carcinoma 
patients [39]. A Phase II study of RCC patients receiving at 
least two 4-day cycles of individualized doses of 5T4Fab–SEA 
(ABR-214936) treatment approximately 1 month apart has 
been completed. When stratified by the Motzer prognostic 
criteria, there is a prolonged survival compared with published 
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expectation. The group of patients receiving the highest drug 
exposure lived almost twice as long as expected, while the 
low-dose group lived as expected from their Motzer scores [40]. 
The increase in circulating IL-2 levels after treatment provides 
a useful biomarker for clinical effect since patients with the 
highest increase in IL-2 at the second treatment day lived sig-
nificantly longer [40]. The next generation of drug, known as 
ABR-217620 or ANYARA, has been developed. The principle 
advantages are reduced binding to preformed superantigen-
specific antibodies, lower toxicity, higher affinity for 5T4 and 
improved tumor cell killing [41]. ABR-217620 was shown to be 
safe for the treatment of RCC and non-small-cell lung carcinoma 
in a Phase I trial and demonstrated evidence of immunological 
and anti-tumor activities [42]. A randomized Phase II/III trial 
of ABR-217620 combined with IFN-a versus IFN-a alone in 
patients with advanced RCC has been completed, and clinical 
and immunological results are awaited.
T-cell-based immunotherapy
In adoptive cell therapy, tumor-specific T cells isolated from 
peripheral blood mononuclear cells or TILs could be expanded 
ex vivo prior to infusion into patients. T-cell-based immunother-
apy using natural or gene-modified T cells has shown success 
for treating metastatic melanoma. However, similar attempts in 
MRCC have not been encouraging and we have recently reviewed 
the potential strategies for improving the efficacy of T-cell-based 
immunotherapy in MRCC [43]. 
“5T4 oncofetal antigen is a suitable 
tumor-associated antigen target for 
immunotherapeutic approaches in renal 
cell carcinoma.”
Another way to harness T cells with the specificity of antibody 
is via their transduction to express chimeric immune receptors 
(CIRs) consisting of a scFv fused to an extracellular spacer 
domain, coupled to a transmembrane and cytosolic region 
of a key signaling molecule (CD3z). Although 5T4 has not 
yet been used as a target for T-cell therapy in clinical trials, a 
CIR that targets 5T4 has been tested in vitro [14]. T cells from 
RCC patients can be used to generate CIR effectors able to kill 
5T4-expressing RCC cells in vitro [14]. This could be a power-
ful strategy that bypasses a number of mechanisms that allow 
tumors to escape T-cell killing and it can be readily scaled up for 
clinical use [44]. Other preclinical studies have generated murine 
T cells expressing CIR against h5T4 and evaluated their tumor 
therapeutic efficacy alone and in combination with immuniza-
tion using a replication defective adenoviral h5T4 vaccine and 
bone marrow-derived dendritic cells (DCs). In the B16-h5T4 
melanoma model, early local subcutaneous, but not systemic 
administration of syngeneic 5T4-specific CIR T cells resulted 
in significantly improved survival [45]. This anti-tumor activ-
ity was enhanced when combined with a post-tumor challenge 
immunization with vaccine followed by post-CIR T-cell treat-
ment with DCs. This synergistic effect was lost without delivery 
of the DCs. These findings suggest that combining engineered 
T cells with specific vaccination strategies can improve the 
active tumor therapy [45].
Conclusion
Renal cell carcinoma remains a difficult malignancy to treat, 
with immunotherapy being an option that can achieve durable 
objective responses, albeit sporadically. 5T4 oncofetal antigen 
is a suitable TAA target for immunotherapeutic approaches in 
RCC. Large-scale trials of both vaccines and antibody-based 
therapies have been completed and the full results are eagerly 
awaited. T-cell-based immunotherapy targeting h5T4 warrants 
further investigation using either natural or gene modified 
5T4-specific T cells. Further evaluation and development of 5T4 
immune targeting by combining with other immunotherapeutic 
modalities (e.g., cytokines, Treg depletion/inhibition or anti-
CTLA4) in selected cancer patients may provide synergy and 
improved clinical outcomes. Identifying biomarkers prognos-
tic of patient clinical response and/or immune parameters that 
correlate with efficacy is of prime importance. With respect to 
TroVax, candidate biomarkers for further investigation include 
pre-existing lymphocyte proliferative response, vaccine-induced 
5T4-specific antibody and/or lymphoproliferative responses, as 
well as the balance of TILs phenotype.
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